TAZVERIK(tazemetostat) Now Approved for the Treatment of Relapsed/Refractory Follicular Lymphoma, Available from Onco360

LOUISVILLE, Ky.--()--Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK (Tazemetostat), a new oral treatment for adult with relapsed/refractory follicular lymphoma whose tumors are positive for an EZH2-mutation as detected by an U.S. Food and Drug Administration (FDA)-approved test and who have received at least two prior systemic therapies or for adult patients with relapsed/refractory follicular lymphoma who have no satisfactory alternative treatment options.

“The approval of TAZVERIK as a treatment option for patients with relapsed/refractory follicular lymphoma is an important advancement in fighting this devastating disease,” said Paul Jardina, President and CEO, Onco360. “As a specialty oncology pharmacy, we are committed to improving the lives of cancer patients suffering from follicular lymphoma.”

Follicular lymphoma is the second-most common type of non-Hodgkin lymphoma and is considered to be indolent, yet incurable. According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, approximately 12,600 patients are diagnosed with follicular lymphoma on an annual basis. When considering all stages of the disease, follicular lymphoma has a five-year overall survival of 89%. Approximately 30% of follicular lymphoma patients are found to have EZH2-mutations.

TAZVERIK is manufactured by Epizyme, a global, commercial-stage, research-based biotechnology company, and was previously approved by the FDA in January 2020 for the treatment of adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The FDA’s approval of TAZVERIK for relapsed/refractory follicular lymphoma is based on the results of two open-label, single-arm cohorts of the Phase I/II E7438-G000-101 clinical trial (NCT01897571) which demonstrated a 69% overall response rate in EZH2-mutant relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy and a 34% overall response rate in EZH2-wild-type relapsed/refractory follicular lymphoma patients who received at least two prior lines of systemic therapy. For full prescribing information, visit TAZVERIK.com.

About Onco360® Oncology Pharmacy:

Onco360 is the largest independent Oncology Pharmacy and clinical support services company in the country. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC- and ACHC -accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Onco360.com.

Contacts

Leigh White
Vice President, Communications and PR
502.630.7412
communication@brightspringhealth.com

Contacts

Leigh White
Vice President, Communications and PR
502.630.7412
communication@brightspringhealth.com